137 related articles for article (PubMed ID: 30327180)
21. Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.
Gross ME; Agus DB; Dorff TB; Pinski JK; Quinn DI; Castellanos O; Gilmore P; Shih JC
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):61-68. PubMed ID: 32123315
[TBL] [Abstract][Full Text] [Related]
22. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
[TBL] [Abstract][Full Text] [Related]
23. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.
Paller CJ; Rudek MA; Zhou XC; Wagner WD; Hudson TS; Anders N; Hammers HJ; Dowling D; King S; Antonarakis ES; Drake CG; Eisenberger MA; Denmeade SR; Rosner GL; Carducci MA
Prostate; 2015 Oct; 75(14):1518-25. PubMed ID: 26012728
[TBL] [Abstract][Full Text] [Related]
24. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
Chee KG; Longmate J; Quinn DI; Chatta G; Pinski J; Twardowski P; Pan CX; Cambio A; Evans CP; Gandara DR; Lara PN
Clin Genitourin Cancer; 2007 Dec; 5(7):433-7. PubMed ID: 18272025
[TBL] [Abstract][Full Text] [Related]
25. Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.
Abrahamsson PA; Boccon-Gibod L; Morote J; de Jong IJ; Malmberg A; Neijber A; Albers P
Eur Urol Focus; 2017 Oct; 3(4-5):470-479. PubMed ID: 28753747
[TBL] [Abstract][Full Text] [Related]
26. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial.
Antonarakis ES; Kibel AS; Yu EY; Karsh LI; Elfiky A; Shore ND; Vogelzang NJ; Corman JM; Millard FE; Maher JC; Chang NN; DeVries T; Sheikh NA; Drake CG;
Clin Cancer Res; 2017 May; 23(10):2451-2459. PubMed ID: 27836866
[No Abstract] [Full Text] [Related]
27. A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.
Dorff TB; Groshen S; Tsao-Wei DD; Xiong S; Gross ME; Vogelzang N; Quinn DI; Pinski JK
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):359-65. PubMed ID: 25245366
[TBL] [Abstract][Full Text] [Related]
28. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.
Paller CJ; Olatoye D; Xie S; Zhou X; Denmeade SR; Eisenberger MA; Antonarakis ES; Carducci MA; Rosner GL
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):28-33. PubMed ID: 24100642
[TBL] [Abstract][Full Text] [Related]
29. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract][Full Text] [Related]
30. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
31. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Liu C; Zhu Y; Su H; Xu X; Zhang Y; Ye D; Hu S
Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
[TBL] [Abstract][Full Text] [Related]
32. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.
Paller CJ; Ye X; Wozniak PJ; Gillespie BK; Sieber PR; Greengold RH; Stockton BR; Hertzman BL; Efros MD; Roper RP; Liker HR; Carducci MA
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):50-5. PubMed ID: 22689129
[TBL] [Abstract][Full Text] [Related]
33. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
[TBL] [Abstract][Full Text] [Related]
34. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.
Suzman DL; Zhou XC; Zahurak ML; Lin J; Antonarakis ES
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):49-55. PubMed ID: 25384338
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
[TBL] [Abstract][Full Text] [Related]
36. Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer.
Hanlon AL; Horwitz EM; Hanks GE; Pollack A
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):43-52. PubMed ID: 14697419
[TBL] [Abstract][Full Text] [Related]
37. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
38. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer.
Grossfeld GD; Chaudhary UB; Reese DM; Carroll PR; Small EJ
Urology; 2001 Aug; 58(2):240-5. PubMed ID: 11489710
[TBL] [Abstract][Full Text] [Related]
39. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
40. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
